PHARMA-7081

PHARMANIAGA BERHAD

Last Price: 0.36

TTM Dividend Yield : 0%

Coming Quarter Report: ~ 2024-11-29

Sector: Pharmaceuticals

Pharmaniaga Berhad is an investment holding company. The Company’s principal activities include manufacturing of generic pharmaceuticals, logistics and distribution, sales and marketing, supply of medical products and services, including hospital equipment, and trading and wholesaling of consumer products. The Company operates through two segments: Logistics and distribution, and Manufacturing. The Logistics and distribution segment is engaged in the distribution, trading and wholesaling of pharmaceutical and medical products, as well as supply and installation of medical and hospital equipment in Malaysia and Indonesia. It also includes supply chain management, order management and warehousing. The Manufacturing segment is engaged in manufacturing of pharmaceutical products. The product portfolio includes oral solid dosages, liquid, cream and small volume injectables. It manufactures general pharmaceutical, including penicillin, cephalosporin and over-the-counter (OTC) products.

**Do feedback to us if you see any error on the data

**Data before 2015 may not be accurate

**Dividend Yield calculated base on the last price of the year

PHARMA Dividend Yield Trend

PHARMA Quarter DY Yield

Year	Financial Year	DY_Type	Announced	EX Date	Payment Date	DY($)	Yield%
2022	31/12/2022	Third Interim	30/11/2022	08/12/2022	06/01/2023	0.006	1.10
2022	31/12/2022	Second Interim	19/08/2022	09/09/2022	04/10/2022	0.005	0.92
2022	31/12/2022	First Interim	20/05/2022	07/06/2022	06/07/2022	0.008	1.47
2021	31/12/2021	Fourth Interim	17/02/2022	07/03/2022	05/04/2022	0.05	9.17
2021	31/12/2021	Third Interim	19/11/2021	06/12/2021	29/12/2021	0.02	3.67
2021	31/12/2021	Second Interim	20/08/2021	07/09/2021	30/09/2021	0.015	2.75
2021	31/12/2021	Interim	21/05/2021	04/06/2021	06/07/2021	0.04	7.34
2020	31/12/2020	Interim	17/03/2021	30/03/2021	22/04/2021	0.01	1.83
2020	31/12/2020	Interim	19/11/2020	04/12/2020	29/12/2020	0.015	2.75
2020	31/12/2020	Interim	19/08/2020	07/09/2020	06/10/2020	0.025	4.59
2020	31/12/2020	Interim	19/05/2020	04/06/2020	30/06/2020	0.06	11.01
2019	31/12/2019	Second Interim	23/08/2019	11/09/2019	11/10/2019	0.025	4.59
2019	31/12/2019	First Interim	16/05/2019	03/06/2019	27/06/2019	0.06	11.01
2018	31/12/2018	Interim	21/02/2019	08/03/2019	10/04/2019	0.02	3.67
2018	31/12/2018	Interim	19/11/2018	03/12/2018	03/01/2019	0.05	9.17
2018	31/12/2018	Second Interim	17/08/2018	03/09/2018	18/09/2018	0.04	7.34
2018	31/12/2018	First Interim	16/05/2018	30/05/2018	20/06/2018	0.05	9.17
2017	31/12/2017	Interim	27/02/2018	13/03/2018	28/03/2018	0.06	11.01
2017	31/12/2017	Interim	15/11/2017	29/11/2017	15/12/2017	0.05	9.17
2017	31/12/2017	Interim	16/08/2017	29/08/2017	15/09/2017	0.04	7.34
2017	31/12/2017	Interim	16/05/2017	29/05/2017	07/06/2017	0.04	7.34
2016	31/12/2016	Interim	21/02/2017	07/03/2017	17/03/2017	0.03	5.50
2016	31/12/2016	Interim	21/11/2016	05/12/2016	15/12/2016	0.04	7.34
2016	31/12/2016	Interim	19/08/2016	02/09/2016	20/09/2016	0.05	9.17
2016	31/12/2016	Interim	13/05/2016	01/06/2016	28/06/2016	0.04	7.34
2015	31/12/2015	Interim	15/02/2016	01/03/2016	25/03/2016	0.07	12.84
2015	31/12/2015	Interim	26/11/2015	09/12/2015	21/12/2015	0.09	16.51
2015	31/12/2015	Interim	17/08/2015	01/09/2015	15/09/2015	0.07	12.84
2015	31/12/2015	Interim	18/05/2015	01/06/2015	25/06/2015	0.07	12.84
2014	31/12/2014	Interim	23/02/2015	09/03/2015	26/03/2015	0.12	22.02
2014	31/12/2014	Interim	21/11/2014	05/12/2014	30/12/2014	0.08	14.68
2014	31/12/2014	Interim	21/08/2014	05/09/2014	24/09/2014	0.04	7.34
2014	31/12/2014	Interim	14/05/2014	29/05/2014	16/06/2014	0.04	7.34
2013	31/12/2013	Interim	24/02/2014	10/03/2014	02/04/2014	0.062	11.38
2013	31/12/2013	Interim	19/11/2013	03/12/2013	24/12/2013	0.03	5.50
2013	31/12/2013	Second Interim	16/08/2013	30/08/2013	24/09/2013	0.0341	6.26
2013	31/12/2013	First Interim	15/05/2013	30/05/2013	28/06/2013	0.075	13.76
2012	31/12/2012	Interim	18/02/2013	04/03/2013	27/03/2013	0.1	18.35
2012	31/12/2012	Interim	06/11/2012	21/11/2012	17/12/2012	0.1	18.35
2012	31/12/2012	Second Interim	08/08/2012	23/08/2012	12/09/2012	0.075	13.76
2012	31/12/2012	First Interim	03/05/2012	16/05/2012	18/06/2012	0.075	13.76
2011	31/12/2011	Second Interim	21/02/2012	08/03/2012	28/03/2012	0.21	38.53
2011	31/12/2011	First Interim	21/12/2011	06/01/2012	26/01/2012	0.09	16.51
2010	31/12/2010	Interim	20/07/2010	02/08/2010	19/08/2010	0.1	18.35
2009	31/12/2009	Interim	05/05/2010	10/06/2010	15/07/2010	0.37	67.89
2002	31/12/2002	Interim	22/11/2002	13/12/2002	26/12/2002	0.025	4.59

PHARMA Annual DY Yield

Year	Annual DY($)	Frequency per yr	SpecialDY	Yield%
2022	0.019	3	No	3.49
2021	0.125	4	No	22.94
2020	0.11	4	No	20.18
2019	0.085	2	No	15.60
2018	0.16	4	No	29.36
2017	0.19	4	No	34.86
2016	0.16	4	No	29.36
2015	0.3	4	No	55.05
2014	0.28	4	No	51.38
2013	0.2011	4	No	36.90
2012	0.35	4	No	64.22
2011	0.3	2	No	55.05
2010	0.1	1	No	18.35
2009	0.37	1	No	67.89
2002	0.025	1	No	4.59

PHARMA Quarter Report History

Q Date	Announced	Revenue	P/L	EPS	Margin	QoQ%	YoY%
30/06/2024	21/08/2024	838,300,000	2,800,000.00	0.19	0.33	-89.06	40.00
31/03/2024	27/05/2024	965,000,000	25,600,000.00	1.78	2.65	178.29	884.62
31/12/2023	29/02/2024	789,800,000	-32,700,000.00	-2.39	-4.14	33.67	94.93
30/09/2023	29/11/2023	885,500,000	-49,300,000.00	-3.67	-5.57	-2,565.00	-673.26
30/06/2023	11/08/2023	848,700,000	2,000,000.00	0.15	0.24	-23.08	177.01
31/03/2023	18/05/2023	880,500,000	2,600,000.00	0.20	0.30	100.40	-90.61
31/12/2022	27/02/2023	862,700,000	-644,400,000.00	-49.19	-74.70	-7,593.02	-853.68
30/09/2022	24/11/2022	924,700,000	8,600,000.00	0.66	0.93	1,091.14	-82.73
30/06/2022	19/08/2022	761,100,000	722,000.00	0.06	0.09	-97.39	-94.73
31/03/2022	20/05/2022	962,200,000	27,700,000.00	2.12	2.88	-67.60	19.91

PHARMA Quarter Profit Trend

PHARMA Annual Profit Trend

Cash Flow

In financial accounting, operating cash flow (OCF), cash flow provided by operations, cash flow from operating activities (CFO) or free cash flow from operations (FCFO), refers to the amount of cash a company generates from the revenues it brings in, excluding costs associated with long – term investment on capital items or investment in securities.(From Wiki)

PHARMA Annual Cash Flow

ROE & Payout Ratio

Return on equity (ROE) is a measure of financial performance calculated by dividing net income by shareholders’ equity. Because shareholders’ equity is equal to a company’s assets minus its debt, ROE is considered the return on net assets. ROE is considered a measure of the profitability of a corporation in relation to stockholders’ equity. (From Investopedia)

The payout ratio is a financial metric showing the proportion of earnings a company pays its shareholders in the form of dividends, expressed as a percentage of the company’s total earnings. On some occasions, the payout ratio refers to the dividends paid out as a percentage of a company’s cash flow. The payout ratio is also known as the dividend payout ratio. (From Investopedia)

PHARMA Annual ROE & Payout Ratio

0 Comments

VictorFoo March 7, 2022 at 4:25 pm

Pharmaniaga Bhd is engaged in the manufacture of generic pharmaceuticals and medical devices, sales and marketing as well as the distribution of medical products and hospital equipment. The company is also involved in logistics and distribution. The group operates in three segments – Logistics and distribution, Manufacturing, and Indonesia. Maximum revenue is generated by the Logistics and distribution segment.

Dividends.my

Malaysia Dividends Ranking Website